324 related articles for article (PubMed ID: 22330319)
21. 18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma.
Subramaniam RM; Wilcox B; Aubry MC; Jett J; Peller PJ
J Med Imaging Radiat Oncol; 2009 Apr; 53(2):160-9; quiz 170. PubMed ID: 19527361
[TBL] [Abstract][Full Text] [Related]
22. Histology of the pleural rind at [
Soltermann A; Opitz I; Burger IA
Pathol Res Pract; 2021 Dec; 228():153660. PubMed ID: 34749212
[TBL] [Abstract][Full Text] [Related]
23. Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma.
Abakay A; Komek H; Abakay O; Palanci Y; Ekici F; Tekbas G; Tanrikulu AC
Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1233-41. PubMed ID: 23690193
[TBL] [Abstract][Full Text] [Related]
24. Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication.
Bille A; Chicklore S; Okiror L; Cook GJ; Spicer J; Landau D; Lang-Lazdunski L
Nucl Med Commun; 2013 Nov; 34(11):1075-83. PubMed ID: 23963351
[TBL] [Abstract][Full Text] [Related]
25. Monitoring of chemotherapy response in malignant pleural mesothelioma using fluorodeoxyglucose positron emission tomography.
Kimura T; Koyama K; Kudoh S; Kawabe J; Yoshimura N; Mitsuoka S; Shiomi S; Hirata K
Intern Med; 2008; 47(23):2053-6. PubMed ID: 19043260
[TBL] [Abstract][Full Text] [Related]
26. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
Mavi A; Basu S; Cermik TF; Urhan M; Bathaii M; Thiruvenkatasamy D; Houseni M; Dadparvar S; Alavi A
Mol Imaging Biol; 2009; 11(5):369-78. PubMed ID: 19472014
[TBL] [Abstract][Full Text] [Related]
27. Dual time point FDG PET for evaluation of malignant pleural mesothelioma.
Yamamoto Y; Kameyama R; Togami T; Kimura N; Ishikawa S; Yamamoto Y; Nishiyama Y
Nucl Med Commun; 2009 Jan; 30(1):25-9. PubMed ID: 19306511
[TBL] [Abstract][Full Text] [Related]
28. Malignant pleural mesothelioma: utility of 18 F-FDG PET.
Spitilli MG; Treglia G; Calcagni ML; Giordano A
Ann Ital Chir; 2007; 78(5):393-6. PubMed ID: 18338546
[TBL] [Abstract][Full Text] [Related]
29. Oxidized low-density lipoprotein stimulates macrophage 18F-FDG uptake via hypoxia-inducible factor-1α activation through Nox2-dependent reactive oxygen species generation.
Lee SJ; Thien Quach CH; Jung KH; Paik JY; Lee JH; Park JW; Lee KH
J Nucl Med; 2014 Oct; 55(10):1699-705. PubMed ID: 25214643
[TBL] [Abstract][Full Text] [Related]
30. [
de Koster EJ; van Engen-van Grunsven ACH; Bussink J; Frielink C; de Geus-Oei LF; Kusters B; Peters H; Oyen WJG; Vriens D;
Mol Imaging Biol; 2023 Jun; 25(3):483-494. PubMed ID: 36253663
[TBL] [Abstract][Full Text] [Related]
31. Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.
Francis RJ; Segard T; Morandeau L; Lee YC; Millward MJ; Segal A; Nowak AK
Lung Cancer; 2015 Oct; 90(1):55-60. PubMed ID: 26259878
[TBL] [Abstract][Full Text] [Related]
32. Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma.
Kasahara N; Kaira K; Bao P; Higuchi T; Arisaka Y; Erkhem-Ochir B; Sunaga N; Ohtaki Y; Yajima T; Kosaka T; Oyama T; Yokobori T; Asao T; Nishiyama M; Tsushima Y; Kuwano H; Shimizu K; Mogi A
Lung Cancer; 2018 May; 119():71-77. PubMed ID: 29656756
[TBL] [Abstract][Full Text] [Related]
33. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography.
Bos R; van Der Hoeven JJ; van Der Wall E; van Der Groep P; van Diest PJ; Comans EF; Joshi U; Semenza GL; Hoekstra OS; Lammertsma AA; Molthoff CF
J Clin Oncol; 2002 Jan; 20(2):379-87. PubMed ID: 11786564
[TBL] [Abstract][Full Text] [Related]
34. Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.
Kitajima K; Doi H; Kuribayashi K
Jpn J Radiol; 2016 Aug; 34(8):537-47. PubMed ID: 27222020
[TBL] [Abstract][Full Text] [Related]
35.
Elliott HS; Metser U; de Perrot M; Cho J; Bradbury P; Veit-Haibach P; Hussey D; Noam T
Br J Radiol; 2018 Jun; 91(1086):20170814. PubMed ID: 29498536
[TBL] [Abstract][Full Text] [Related]
36. Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer.
Kasahara N; Kaira K; Yamaguchi K; Masubuchi H; Tsurumaki H; Hara K; Koga Y; Sakurai R; Higuchi T; Handa T; Oyama T; Yokobori T; Shimizu K; Asao T; Hisada T
Lung Cancer; 2019 Aug; 134():180-186. PubMed ID: 31319979
[TBL] [Abstract][Full Text] [Related]
37. Relationship between 18F-FDG accumulation and lactate dehydrogenase A expression in lung adenocarcinomas.
Zhou X; Chen R; Xie W; Ni Y; Liu J; Huang G
J Nucl Med; 2014 Nov; 55(11):1766-71. PubMed ID: 25342384
[TBL] [Abstract][Full Text] [Related]
38. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
Ceresoli GL; Chiti A; Zucali PA; Rodari M; Lutman RF; Salamina S; Incarbone M; Alloisio M; Santoro A
J Clin Oncol; 2006 Oct; 24(28):4587-93. PubMed ID: 17008700
[TBL] [Abstract][Full Text] [Related]
39. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
Ma WW; Jacene H; Song D; Vilardell F; Messersmith WA; Laheru D; Wahl R; Endres C; Jimeno A; Pomper MG; Hidalgo M
J Clin Oncol; 2009 Jun; 27(16):2697-704. PubMed ID: 19380450
[TBL] [Abstract][Full Text] [Related]
40. Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
Marin-Oyaga VA; Salavati A; Houshmand S; Pasha AK; Gharavi M; Saboury B; Basu S; Torigian DA; Alavi A
Hell J Nucl Med; 2015; 18(1):11-8. PubMed ID: 25679073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
